Recommended

Explore the six core considerations for success in clinical trials in this upcoming webinar, register your details to secure your place today!

List view / Grid view

Articles

What is label-free screening and why use it in drug discovery?
What is label-free screening and why use it in drug discovery?

What is label-free screening and why use it in drug discovery?

18 December 2012 | By Matthew A. Cooper and Reena Halai, Institute for Molecular Bioscience, the University of Queensland

In the journey of a molecule from its origins in a compound library to candidate drug status, a large variety of profiling must occur to define activity, selectivity, potency, adverse effects, pharmacology and in vivo efficacy. Advances in biophysical methods that can analyse drug interactions with a molecular target, a…

Drug discovery assays for the histone deacetylase class of enzymes
Drug discovery assays for the histone deacetylase class of enzymes

Drug discovery assays for the histone deacetylase class of enzymes

18 December 2012 | By Sheraz Gul and Gesa Witt, European ScreeningPort GmbH

The histone deacetylase (HDAC) class of enzyme are a group of conserved enzymes known for their ability to remove acetyl groups from lysine residues on histone tails. Since aberrant HDAC enzyme expression is observed in various diseases, there is increasing interest in finding small molecules which function as HDAC enzyme…

Table 1: Confounding effects influencing measured RNA levels
Table 1: Confounding effects influencing measured RNA levels

RNA quality matters

18 December 2012 | By Mikael Kubista, Jens Björkman, David Svec and Robert Sjöback, TATAA Biocenter

RNA levels can be measured with very high specificity, sensitivity and accuracy with techniques such as real-time quantitative PCR (qPCR), microarray analysis and next generation sequencing. This makes messenger (m) RNAs and potentially microRNAs and other non-coding RNAs popular as biomarkers. But RNA is less stable and more dynamic than…

Under the Microscope: John Comer, Sirius Analytical

18 December 2012 | By Helen Bahia, Editor, European Pharmaceutical Review

John Comer, Chief Scientific Officer at Sirius Analytical, discusses particle size analysis and characterisation. Sirius Analytical was founded in 1989 with the goal to become a world-class manufacturer of innovative instrumentation for chemical analysis. Today, Sirius Analytical makes instruments to measure the physicochemical properties of drugs, specifically pKa, logP, solubility…

Rapid micro methods and the next generation in ATP bioluminescence

25 October 2012 | By Michael J. Miller, President, Microbiology Consultants, LLC and Noe Miyashita, Researcher, Hitachi Plant Technologies, Ltd

This is the fifth paper in our continuing series on Rapid Microbiological Methods (RMM) that will appear in European Pharmaceutical Review during 2012. As many of you know, I am always on the lookout for the next generation of rapid microbiological method (RMM) technologies and solutions. In this article, I…

qPCR In-Depth Focus 2012
qPCR In-Depth Focus 2012

qPCR In-Depth Focus 2012

24 October 2012 | By

In this qPCR In-Depth Focus: Setting the bar; Q & A - Mikael Kubista from the TATAA Biocenter poses five questions for Jay Brock, Senior Manager, Applications and Technical Support, USB® Life Science Reagents from Affymetrix; Not your grandfathers’ real-time PCR...

Biologics: Teamwork pays off in race to expand market for monoclonal antibodies

22 October 2012 | By Bahija Jallal, Executive Vice President, Research & Development, MedImmune

The first biologic drug – infliximab (Remicade) – was launched in 1998 with initial sales of USD 500 million per annum. By 2010, Reuters’ top 10 drugs by sales included five biologics (Remicade, Enbrel, Humira, Avastin and Humira) generating around USD 34 billion in revenue, including USD 7.4 billion from…

Applications of MRI to controlled drug delivery devices

22 October 2012 | By Mick Mantle, Department of Chemical Engineering & Biotechnology, University of Cambridge

Magnetic resonance imaging (MRI) is a technique that is traditionally used as a diagnostic clinical imaging tool. However, there are now an increasing number of non-medial applications where MRI has seen unrivalled success. One of those areas is in its application to pharmaceutical research. The aim of this article is…

Figure 1: Typical product temperature profiles during uncontrolled nucleation indicated by thermocouples placed centre bottom within the vial. 1: degree of supercooling; 2: nucleation temperature, Tn; 3: equilibrium freezing temperature, Tf.
Figure 1: Typical product temperature profiles during uncontrolled nucleation indicated by thermocouples placed centre bottom within the vial. 1: degree of supercooling; 2: nucleation temperature, Tn; 3: equilibrium freezing temperature, Tf.

Controlled nucleation in freeze-drying

22 October 2012 | By Henning Gieseler, Associate Professor at the Division of Pharmaceutics, University of Erlangen & CEO, GILYOS GmbH and Peter Stärtzel, Pharmaceutical Scientist, GILYOS GmbH

The stochastic nature of nucleation during the freezing step of the freeze-drying process has been regarded as a demerit in a process which is considered under rigorous control. The freezing performance of a product can impact its subsequent drying behaviour and the final product quality attributes. Hence, the idea to…

Preparing biocompatible materials for non-permanent medical devices

22 October 2012 | By Vinod B. Damodaran and Jessica M. Joslin, Department of Chemistry, Colorado State University and Melissa M. Reynolds, Department of Chemistry and School of Biomedical Engineering, Colorado State University

Biodegradable polymers comprise an important class of biomaterials due to their ability to satisfy short-term requirements for medical applications where a permanent implant is not required. However, current biodegradable polymers suffer from undesirable chemical properties that lead to improper elimination from the body and potentially toxic by-products. Additionally, medical polymers…

0813 TSP China PR
0813 TSP China PR

Evolving landscape of pharmaceutical outsourcing in China

22 October 2012 | By Xiaorong He, Senior Research Fellow, Boehringer-Ingelheim

China’s economic growth has shocked and awed the world, with its GDP growing at an average rate of 10 per cent for 30 years. The astonishing economic growth has also spurred rapid growth of pharmaceutical outsourcing business in China. In the past, China had been the major source of raw…